Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis.

ABSTRACT:

Background

Antibody-drug conjugates are attractive targeted agents in anticancer treatment because of their unique mechanism of action and reduced toxicity. Little is known about the spectrum of adverse events associated with antibody-drug conjugates, despite tens of clinical trials.

Methods

A systematic review of randomized controlled trials evaluating antibody-drug conjugate efficacy in anticancer treatment was conducted. PubMed, EMBASE, and ClinicalTrial.gov were searched for relevant studies. Meta-analyses assessed the odds ratios (ORs) of 12 treatment-related symptoms and toxicities in patients treated with antibody-drug conjugates compared with those receiving other anticancer agents without antibody-drug conjugates. All-grade and high-grade (grade ≥3) toxicities were

SUBMITTER: Suzuki Y 

PROVIDER: S-EPMC10579782 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature